UBR5 over-expression contributes to poor prognosis and tamoxifen resistance of ERa+ breast cancer by stabilizing β-catenin.

MLA

Yang, Yanfang, et al. “UBR5 Over-Expression Contributes to Poor Prognosis and Tamoxifen Resistance of ERa+ Breast Cancer by Stabilizing β-Catenin.” Breast Cancer Research & Treatment, vol. 184, no. 3, Dec. 2020, pp. 699–710. EBSCOhost, https://doi.org/10.1007/s10549-020-05899-6.

APA

Yang, Y., Zhao, J., Mao, Y., Lin, G., Li, F., & Jiang, Z. (2020). UBR5 over-expression contributes to poor prognosis and tamoxifen resistance of ERa+ breast cancer by stabilizing β-catenin. Breast Cancer Research & Treatment, 184(3), 699–710. https://doi.org/10.1007/s10549-020-05899-6

Chicago

Yang, Yanfang, Jing Zhao, Yiran Mao, Gu Lin, Fangxuan Li, and Zhansheng Jiang. 2020. “UBR5 Over-Expression Contributes to Poor Prognosis and Tamoxifen Resistance of ERa+ Breast Cancer by Stabilizing β-Catenin.” Breast Cancer Research & Treatment 184 (3): 699–710. doi:10.1007/s10549-020-05899-6.